[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336419-105":59,"doc-detail-336419-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","increasing-the-dye-payload-of-cetuximab-irdye800cw-enables-photodynamic-therapy","Increasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy","","Cetuximab (Cet)-IRDye800CW and related antibody-IRDye800CW conjugates are proposed to delineate tumor margins during fluorescence image-guided surgery, yet residual disease can still drive recurrence. This study evaluates antibody-targeted photodynamic therapy after IGS as a way to restore molecular specificity. Increasing dye payload from 2 to 11 per antibody enables in vitro singlet oxygen, hydroxyl radicals, and peroxynitrite generation under 810 nm light, with up to 90% phototoxicity in FaDu cells while preserving cancer-cell binding selectivity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/increasing-the-dye-payload-of-cetuximab-irdye800cw-enables-photodynamic-therapy/336419/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/increasing-the-dye-payload-of-cetuximab-irdye800cw-enables-photodynamic-therapy/336419.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How does dye payload increase affect Cet-IRDye800CW photodynamic activity?","Question",{"text":113,"@type":114},"Increasing the dye payload from 2 (clinical version) to 11 per antibody enables antibody-targeted PDT in vitro under 810 nm activation, producing multiple reactive species and stronger phototoxic effects.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What reactive oxygen species are generated by Cet-IRDye800CW (1:11)?",{"text":118,"@type":114},"Upon activation with 810 nm light, Cet-IRDye800CW (1:11) generates singlet oxygen, hydroxyl radicals, and peroxynitrite.",{"name":120,"@type":111,"acceptedAnswer":121},"How does Cet-IRDye800CW (1:11) perform regarding cancer-cell specificity and toxicity controls?",{"text":122,"@type":114},"In vitro assays confirm maintained cancer cell binding specificity, and Cet-IRDye800CW (1:11) shows high phototoxicity with 810 nm light while being less toxic in the dark than the approved indocyanine green chromophore.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336419,1790109562,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","This article is licensed under CC-BY-NC-ND 4.0  \n[pubs.acs.org/molecularpharmaceutics](pubs.acs.org/molecularpharmaceutics)  Article   \nIncreasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy  \nAustin Nguyen, Chanda Bhandari, Micah Keown, Ashritha Malkoochi, Maxwell Quaye, Doha Mahmoud, Nimit Shah, Dina Alzhanova, Colin G. Cameron, Jacopo Ferruzzi, Sherri A. McFarland, Gal Shafirstein, Rolf Brekken, and Girgis Obaid *  \n Cite This: Mol. Pharmaceutics 2024, 21, 3296−3309  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Cetuximab (Cet)-IRDye800CW, among other antibody-IRDye800CW conjugates, is a potentially effective tool for delineating tumor margins during fluorescence image-guided surgery (IGS). However, residual disease often leads to recurrence. Photodynamic therapy (PDT) following IGS is proposed as an approach to eliminate residual disease but suffers from a lack of molecular specificity for cancer cells. Antibody-targeted PDT offers a potential solution for this specificity problem. In this study, we show, for the first time, that Cet-IRDye800CW is capable of antibody-targeted PDT in vitro when the payload of dye molecules is increased from 2 (clinical version) to 11 per antibody. CetIRDye800CW (1:11) produces singlet oxygen, hydroxyl radicals,  \nand peroxynitrite upon activation with 810 nm light. In vitro assays on FaDu head and nk cancer cells confirm that Cet  \nIRDye800CW (1:11) maintains cancer cell binding specificity and is capable of inducing up to 90% phototoxicity in FaDu cancer cells. The phototoxicity of Cet-IRDye800CW conjugates using 810 nm light follows a dye payload-dependent trend. CetIRDye800CW (1:11) is also found to be more phototoxic to FaDu cancer cells and less toxic in the dark than the approved chromophore indocyanine green, which can also act as a PDT agent. We propose that antibody-targeted PDT using high-payload Cet-IRDye800CW (1:11) could hold potential for eliminating residual disease postoperatively when using sustained illumination devices, such as fiber optic patches and implantable surgical bed balloon applicators. This approach could also potentially be applicable to a wide variety of resectable cancers that are amenable to IGS-PDT, using their respective approved full-length antibodies as a template for high-payload IRDye800CW conjugation.  \nKEYWORDS: photodynamic therapy, fluorescence image-guided surgery, antibody-conjugate, Cetuximab, IRDye800CW  \n■ INTRODUCTION  \nIRDye800CW is a near-infrared (NIR) fluorescent dye that has been conjugated to a number of monoclonal antibodies, allowing for fluorescence molecular image-guided surgery (IGS) of multiple resectable cancers (NCT04459065 and NCT02113202) . 1−3 These include Cetuximab (Cet), amonoclonal antibody that binds to the epidermal growth factor receptor (EGFR), to form Cet-IRDye800CW.3,4 CetIRDye800CW can be used to target cancers that overexpress the EGFR and is under investigation in clinical trials for fluorescence IGS of head and neck cancers (NCT05499065, NCT03134846; Phase I/II), glioma (NCT05929456, Phase I), and lung cancer (NCT06101394; Phase I), among others. Due to its ability to specifically accumulate in tumor tissue, CetIRDye800CW has the potential to enhance the accuracy of tumor resection. However, residual unresected disease in positive or close margins causes local recurrence.  \nPhotodynamic therapy (PDT) is a cytotoxic light-activated modality that has been proposed to treat residual unresected  \ndisease following IGS. However, many PDT agents suffer from a lack of specificity to disease tissue, which could damage healthy structures near the surgical bed. Antibody-targeted PDT, also known as photoimmunotherapy, is an alternative approach that benefits from molecular specificity. During antibody-targeted PDT, the antibody targets specific tumor receptors, and a t","cbCaigSFlsMATfiv","https://ap.wps.com/l/cbCaigSFlsMATfiv","pdf",5824999,14,"English","# Abstract\n# Introduction","[{\"question\":\"How does dye payload increase affect Cet-IRDye800CW photodynamic activity?\",\"answer\":\"Increasing the dye payload from 2 (clinical version) to 11 per antibody enables antibody-targeted PDT in vitro under 810 nm activation, producing multiple reactive species and stronger phototoxic effects.\"},{\"question\":\"What reactive oxygen species are generated by Cet-IRDye800CW (1:11)?\",\"answer\":\"Upon activation with 810 nm light, Cet-IRDye800CW (1:11) generates singlet oxygen, hydroxyl radicals, and peroxynitrite.\"},{\"question\":\"How does Cet-IRDye800CW (1:11) perform regarding cancer-cell specificity and toxicity controls?\",\"answer\":\"In vitro assays confirm maintained cancer cell binding specificity, and Cet-IRDye800CW (1:11) shows high phototoxicity with 810 nm light while being less toxic in the dark than the approved indocyanine green chromophore.\"}]","Increasing the Dye Payload of Cetuximab-IRDye800CW Enables Photodynamic Therapy | PDF",1790014955,35]